Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

44.50USD
22 Nov 2017
Change (% chg)

$1.85 (+4.34%)
Prev Close
$42.65
Open
$43.25
Day's High
$45.45
Day's Low
$43.25
Volume
240,189
Avg. Vol
186,699
52-wk High
$58.80
52-wk Low
$29.90

Latest Key Developments (Source: Significant Developments)

Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals Inc reports third quarter 2017 financial results.Q3 non-gaap earnings per share $0.11.Q3 gaap loss per share $0.19.Q3 revenue $67.3 million versus I/B/E/S view $69.6 million.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Pacira Pharmaceuticals Inc - ‍Full-year exparel net product sales guidance revised to $280 to $285 million​.Pacira Pharmaceuticals Inc - ‍Updating its full year 2017 sales guidance and reiterating its remaining financial guidance​.FY2017 revenue view $291.8 million -- Thomson Reuters I/B/E/S.  Full Article

Pacira Pharma to invest up to $25 million in Tela Bio
Wednesday, 25 Oct 2017 08:00am EDT 

Oct 25 (Reuters) - Pacira Pharmaceuticals Inc :Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​.Under terms of agreement, Pacira will make an initial investment of $15 million​.Under terms of agreement, Pacira is entitled to one seat on Tela Bio board of directors​.Agreement also includes a standstill provision precluding a change of control in Tela Bio for at least 12 months​.  Full Article

Pacira Pharmaceuticals announces FDA acceptance of SNDA
Wednesday, 18 Oct 2017 07:30am EDT 

Oct 18 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia.Pacira Pharmaceuticals Inc - ‍expected action date by FDA under Prescription Drug User Fee Act (PDUFA) is April 6, 2018​.  Full Article

‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​
Tuesday, 22 Aug 2017 04:25pm EDT 

Aug 22 (Reuters) - Pacira Pharmaceuticals Inc :‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​.  Full Article

Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals
Monday, 14 Aug 2017 06:34am EDT 

Aug 14 (Reuters) - Pacira Pharmaceuticals Inc :Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​.  Full Article

Pacira Pharmaceuticals reports Q2 GAAP loss per share of $0.49
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Pacira Pharmaceuticals Inc ::Pacira pharmaceuticals, inc. Reports second quarter 2017 financial results.Q2 non-GAAP loss per share $0.11.Q2 GAAP loss per share $0.49.Q2 revenue $70.9 million versus I/B/E/S view $73.4 million.Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Pacira pharmaceuticals inc says full-year exparel net product sales guidance of $290 to $310 million reiterated.  Full Article

Pacira announces topline phase 3 results for Exparel
Tuesday, 25 Jul 2017 07:30am EDT 

July 25 (Reuters) - Pacira Pharmaceuticals Inc :Pacira announces topline phase 3 results for Exparel as a single-dose nerve block.‍Lower extremity study defined safety and pharmacokinetic profile through 120 hours​.‍Timing for resubmission of supplemental new drug application remains on track​.‍Upper extremity study showed that Exparel significantly reduces pain scores and opioid use​.  Full Article

Pacira Pharma says President James Scibetta has resigned
Tuesday, 23 May 2017 04:30pm EDT 

May 23 (Reuters) - Pacira Pharmaceuticals Inc :Pacira pharmaceuticals -james scibetta resigning as president to become ceo of an undisclosed private early-stage oncology company.Pacira pharmaceuticals -will allocate scibetta's operational oversight responsibilities to current leadership team, does not intend to name successor.  Full Article

Pacira Pharmaceuticals Inc reports Q1 GAAP loss per share $0.52
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Pacira Pharmaceuticals Inc ::Pacira pharmaceuticals, inc. Reports first quarter 2017 financial results.Q1 non-GAAP loss per share $0.19.Q1 GAAP loss per share $0.52.Q1 revenue $69.3 million versus I/B/E/S view $70.3 million.Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.Says reaffirms FY 2017 exparel net product sales guidance of $290 million to $310 million.  Full Article

Christopher James reports a 5.9 pct passive stake in Pacira Pharmaceuticals
Monday, 17 Apr 2017 06:02am EDT 

April 17 (Reuters) - Pacira Pharmaceuticals Inc :Christopher James reports a 5.9 percent passive stake in Pacira Pharmaceuticals as of April 4, 2017 - SEC filing.  Full Article

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia